Send to

Choose Destination
Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv15-25. doi: 10.1093/ndt/gfu017.

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

Author information

Department of Nephrology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, the Netherlands.
ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Division of Nephrology, Copenhagen University Hospital, Roskilde, Denmark.
Division of Nephrology, University Clinic, University of Würzburg, Würzburg, Germany.
Departamento de Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain.
Department of Nephrology, University Hospital Virgen Macarena, Seville, Spain.
Public Health Directorate, Asturias, Spain.
Richard Bright Renal Unit, Bristol, UK.
REIN Registry, Agence de la Biomedecine, Saint Denis La Plaine, France.
Finnish Registry of Kidney Diseases, Helsinki, Finland.
Department of Nephrology, University of Copenhagen, Herlev Hospital, Herlev, Denmark.
Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Department of Nephrology, Dialysis and Hypertension, Nederlandstalige Belgische Vereniging voor Nefrologie (Dutch Speaking Belgium Renal Registry)-NBVN, AZ Nikolaas, Sint-Niklaas, Belgium.
Department of Nephrology, Hospital del Mar, Barcelona, Spain.
Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, U.O.C. Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera di Reggio Calabria and CNR-IBIM, Reggio Calabria, Italy.
Department of Medicine and Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Subirección General de Epidemiología y Vigilancia de la Salud, Conselleria de Sanitat, Generalitat C. Valenciana, Valencia, Spain Spanish Consortium of Epidemiology and Public Health Research (CIBERESP), Spain.



Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological data on the prevalence of, and survival on RRT for ADPKD.


This study used data from the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by the Kaplan-Meier method and by Cox proportional hazards regression.


From the first to the last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population (pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation 0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the last study period, which will be discussed in detail in a separate study.


In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality. This has led to a considerable increase in the number of ADPKD patients being treated with RRT.


ADPKD; epidemiology; prevalence; renal replacement therapy; survival

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center